CoChat

Are Tricyclic Antidepressants Useful for Mild Depression? A Placebo controlled Trial

Paykel, E., Freeling, P., Hollyman, J. · 1988 · Pharmacopsychiatry
Cited by 74

The DOI matches its Crossref record.

Abstract

Depressions in general practice tend to be mild and non-endogenous. The value of antidepressants and indications for their use in such depressions are not well documented. One hundred and forty one general practice depressives were treated from four to six weeks with amitriptyline in median dose 125 mgs daily or placebo in a randomised controlled trial. Significant drug placebo differences were apparent by two weeks and were strong by six weeks. Detailed examination of symptom ratings showed that the effect was a true antidepressant one, on core symptoms of depression. Interactions were examined between drug-placebo differences and a range of predictor characteristics. There were no significant interactions for demographic characteristics, history of illness or endogenous depression in terms of symptom pattern, absence of life stress or non-neurotic personality. Drug was superior to placebo in all subgroups. Only for initial severity of illness were significant interactions found. Amitriptyline was superior to placebo in probable and definite major depressions on the Research Diagnostic Criteria but not in minor depressions. It was also superior to placebo in patients with initial Hamilton Scale scores of more than 12, but not 6-12. Overall these findings indicate that tricyclic antidepressant is of clear therapeutic benefit in a spectrum of milder depressions except for the most mild of these. Zusammenfassung Die in Allgemeinpraxen behandelten Depressionen sind meist leicht und nichtendogenen Ursprungs. Der Stellenwert der Antidepressiva sowie deren Indikationen sind nicht gut belegt. In einem randomisierten plazebokontrollierten Versuch erhielten 140 depressive Patienten aus Allgemeinpraxen während eines Zeitraums von 4-6 Wochen eine durchschnittliche tägliche Dosis von 125 mg Amitriptylin bzw. Plazebo. Nach 2 Wochen machten sich signifikante Unterschiede zwischen Präparat und Plazebo bemerkbar, die nach Ablauf von 6 Wochen stark ausgeprägt waren. Eine eingehende Untersuchung der Symptombewertungen zeigte, daß die Wirkung des Präparats eine echt antidepressive war und sich auf die Kernsymptome der Depression auswirkte. Es wurden Wechselwirkungen zwischen den Präparat/Plazebo-Unterschieden und einer Reihe von ,,predictive value"-Daten untersucht. Es zeigten sich keine signifikanten Wechselwirkungen für demographische Merkmale, Anamnese der Erkrankung oder endogene Depression hinsichtlich des Symptomenkomplexes, Abwesenheit von Alltagsstreß oder der Merkmale einer nichtneurotischen Persönlichkeit. Bei allen Untergruppen erwies sich das Präparat als dem Plazebo überlegen. Signifikante Wechselwirkungen fanden sich nur bei bereits zu Anfang bestehendem Schweregrad der Erkrankung. Amitryptilin erwies sich als dem Plazebo überlegen bei wahrscheinlichen und gesicherten schweren Depressionen nach den ,,Research Diagnostic Criteria", nicht jedoch bei sehr leichten Depressionen. Es war ebenfalls dem Plazebo überlegen bei Patienten, deren Hamilton Scale Score über 12 lag, nicht jedoch bei solchen mit einem Wert von 6-12. Im ganzen gesehen deuten diese Befunde darauf hin, daß ein trizyklisches Antidepressivum bei einer Reihe leichter Depressionen wirksam ist, mit Ausnahme der leichtesten.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1055/s-2007-1014639

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 74

Metadata

Authors
Paykel, E., Freeling, P., & Hollyman, J.
Venue
Pharmacopsychiatry
Published
1988-01
Volume
21
Issue
01
Pages
15-18
ISSN
  • 0176-3679 (ISSN-L)
  • 1439-0795
OpenAlex
W2054826326
Cited by
74
References
0
FWCI
0.76
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Are Tricyclic Antidepressants Useful for Mild Depression? A Placebo controlled Trial. https://app.cochat.ai/papers/10.1055/s-2007-1014639
The paper
Paykel, E., Freeling, P., & Hollyman, J. (1988). Are Tricyclic Antidepressants Useful for Mild Depression? A Placebo controlled Trial. Pharmacopsychiatry. https://doi.org/10.1055/s-2007-1014639

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.